Mimedx (MDXG) Convertible Debt (2011 - 2012)
Mimedx's (MDXG) quarterly Convertible Debt came in at $4.0 million in Q4 2012, up 46.19% year-on-year from $2.7 million in Q1 2012, and up 14.85% quarter-over-quarter from $3.5 million in Q3 2012.
Mimedx (MDXG) Convertible Debt (2011 - 2012) Analysis & Trends
Mimedx has disclosed Convertible Debt across 2 years of filings, most recently posting $4.0 million for Q4 2012.
- Convertible Debt for Q4 2012 came in at $4.0 million, up 46.19% year-over-year; the trailing twelve-month figure through Dec 2012 was $4.0 million (up 46.19% YoY), and the FY2012 annual result was $4.0 million, up 46.19% from the prior year.
- Convertible Debt came in at $4.0 million for Q4 2012 at Mimedx, up from $3.5 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $4.0 million in Q4 2012 to a low of $959209.0 in Q2 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Mimedx | 546.28 Mn | 386.51 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 4.01 Mn |
| Sep 30, 2012 | 3.49 Mn |
| Jun 30, 2012 | 3.24 Mn |
| Mar 31, 2012 | 3.02 Mn |
| Dec 31, 2011 | 2.74 Mn |
| Jun 30, 2011 | 959,209.00 |